{"product_id":"harrowinc-five-forces-analysis","title":"Harrow Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cpharrow porter five forces snapshot highlights competitive intensity supplier and buyer leverage substitute threats barriers to entry in concise terms it a fast way gauge strategic risk opportunity. unlock the full analysis explore harrow dynamics market pressures advantages detail.\u003e\n\u003c\/pharrow\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of API Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow depends on a small set of qualified API makers for ophthalmic-grade chemicals, a market where 3–5 global suppliers hold ~70% of capacity, raising supplier leverage on price and lead times.\u003c\/p\u003e\n\u003cp\u003eThese APIs require strict GMP and USP standards; in 2024 Harrow reported a 12% COGS rise tied to supplier price hikes and longer 10–14 week lead times.\u003c\/p\u003e\n\u003cp\u003eAny shutdown at a specialized vendor could halt production of Harrow’s core drugs within weeks and risk revenue losses exceeding single-quarter net sales (~$8–12M per product line).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet FDA and current Good Manufacturing Practice (cGMP) rules to stay in Harrow’s pharma chain, raising Harrow’s switching cost since qualifying a new supplier takes 18–36 months and often $1–3M in validation and regulatory filings.\u003c\/p\u003e\n\u003cp\u003eBecause replacement is slow and costly, incumbent suppliers hold leverage in contract talks; industry data shows qualified-supplier counts fell 12% for mid‑sized CDMOs between 2019–2024, tightening supplier power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOphthalmic products need sterile facilities and niche delivery systems, like multi-dose preservative-free bottles, which only about 12–15 CMOs worldwide can reliably produce as of 2025, giving those suppliers outsized leverage; industry reports show CMO margins for specialized ophthalmics run 18–25%, limiting price flexibility. Harrow’s reliance on these few providers reduces its bargaining power, constraining cost cuts and risking supply bottlenecks that could impact gross margin by 100–250 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Input Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhen third parties hold patents on components and delivery tech used in Harrow’s acquired branded portfolio, suppliers can dictate prices and terms; Harrow faces limited leverage for proprietary advanced formulations that drive its 2025 growth plans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatented inputs raise supplier power\u003c\/li\u003e\n\u003cli\u003eHarrow’s reliance on advanced formulations increases cost exposure\u003c\/li\u003e\n\u003cli\u003eExclusive rights force acceptance of supplier pricing\u003c\/li\u003e\n\u003cli\u003eMitigation: licensing, vertical integration, or alternative R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput Price Volatility and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal raw-material price swings—active since 2021 and with active 2024 drug-API spot-price rises of ~12–18% for key inputs—push suppliers to pass costs to firms like Harrow.\u003c\/p\u003e\n\u003cp\u003eHarrow’s smaller scale (estimated 2024 revenues ~USD 350m vs. Pfizer’s USD 58.4bn) limits volume discounts, reducing its bargaining leverage.\u003c\/p\u003e\n\u003cp\u003eThis makes Harrow sensitive to vendor pricing strategies and macro conditions; a 5% input-cost shock could cut margins by ~2–3 percentage points based on 2024 COGS ratios.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 API spot prices up 12–18%\u003c\/li\u003e\n\u003cli\u003eHarrow revenue ~USD 350m (2024 est.)\u003c\/li\u003e\n\u003cli\u003eLarge peers: Pfizer USD 58.4bn (2024)\u003c\/li\u003e\n\u003cli\u003e5% input shock → ~2–3 pp margin hit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTight supplier grip: few API\/CMO sources lift costs—5% shock trims margins 2–3pp\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high leverage: 3–5 global API makers supply ~70% capacity, 12–15 CMOs handle niche ophthalmic delivery, and 2019–24 qualified-supplier counts fell 12%, raising switching costs (18–36 months, $1–3M). Harrow’s 2024 revenue ~USD 350m and 12% COGS rise show sensitivity; a 5% input shock could cut margins ~2–3 pp.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal API suppliers\u003c\/td\u003e\n\u003ctd\u003e3–5 (70% capacity)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified CMOs\u003c\/td\u003e\n\u003ctd\u003e12–15 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier count change\u003c\/td\u003e\n\u003ctd\u003e-12% (2019–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch cost\u003c\/td\u003e\n\u003ctd\u003e18–36 months; $1–3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarrow rev\u003c\/td\u003e\n\u003ctd\u003e~USD 350m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS rise\u003c\/td\u003e\n\u003ctd\u003e12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput shock impact\u003c\/td\u003e\n\u003ctd\u003e5% → -2–3 pp margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces assessment for Harrow that uncovers competitive pressures, supplier and buyer power, threat of substitutes and entrants, and strategic levers to protect market share and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHarrow Porter's Five Forces delivers a one-sheet strategic snapshot—instantly reveal competitive pressure with an editable radar chart and copy-ready layout for rapid boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and insurers act as powerful intermediaries that set formulary placement and patient access for Harrow, often dictating coverage tiers that shape demand.\u003c\/p\u003e\n\u003cp\u003eIf Harrow's drug lands outside a favorable cost tier, patients face higher co-pays and prescription volumes drop—US studies show a 30–40% volume decline when out-of-tier.\u003c\/p\u003e\n\u003cp\u003eTo secure preferred placement, Harrow typically pays large rebates; industry averages show manufacturer rebates to PBMs reached about 35% of list price in 2024.\u003c\/p\u003e\n\u003cp\u003eThese rebate pressures compress Harrow's net price and margins, forcing trade-offs between access, volume, and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Large Eye Care Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe consolidation of US ophthalmology practices into large, private‑equity‑backed groups—over 40% of practices were in MSOs (management services organizations) by 2024—gives buyers strong negotiating leverage. These groups can demand bulk discounts, standardized protocols, and preferred‑vendor status, steering purchases toward specific brands across hundreds of clinics. Harrow must tailor pricing and service bundles to win these high‑volume channels, where a single contract can represent $5M–$50M+ in annual device and supply spend. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpsurgeons and clinics prioritize cost-effective treatments for routine care like cataract surgery inflammation management with us ophthalmology reporting a shift to lower-cost generics or compounded drugs when branded premiums exceed of procedure margins.\u003e\n\u003c\/psurgeons\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Generic Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor many of Harrow's off-patent drugs, buyers can switch to generics sold by multiple firms; US generic market share topped 90% by prescriptions in 2024, pressuring list prices and margins.\u003c\/p\u003e\n\u003cp\u003ePrice transparency and identical substitutes let purchasers demand steeper discounts—Harrow reported gross margin of 28% in FY2024, down 4 pts versus peers due to discounting.\u003c\/p\u003e\n\u003cp\u003eHarrow must prove clinical or service value continually to avoid churn to commodity-priced generics, or face volume and revenue erosion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh generic availability: \u0026gt;90% U.S. prescription share (2024)\u003c\/li\u003e\n\u003cli\u003eMargin impact: Harrow gross margin 28% FY2024\u003c\/li\u003e\n\u003cli\u003eBuyer leverage: multiple suppliers, transparent pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Out-of-Pocket Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppatients are more informed about eye-care options and often request specific or lower-cost treatments surveys show of ophthalmic patients research before visits high out-of-pocket costs push to ask doctors for cheaper therapeutics switch generics creating bottom-up price pressure on harrow keep prices competitive adherence satisfaction.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e68% researched options pre-visit (2024)\u003c\/li\u003e\u003cli\u003e42% requested cheaper alternatives or generics\u003c\/li\u003e\u003cli\u003ePatient pressure influences Harrow pricing and adherence\u003c\/li\u003e\n\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRebates Crush Pricing: 35% Cuts \u0026amp; 90%+ Generics Squeeze Harrow's Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBMs, insurers, and consolidated MSOs wield strong leverage over Harrow—rebates averaged ~35% of list price (2024), cutting net price and margins (Harrow gross margin 28% FY2024). High generic share (\u0026gt;90% U.S. prescriptions, 2024) and patient price-sensitivity (68% research, 42% request cheaper options) force steep discounts or risk volume loss.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturer rebates\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric Rx share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarrow gross margin\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients researching\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients seeking cheaper\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eHarrow Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Harrow Porter Five Forces Analysis you'll receive immediately after purchase—no placeholders, no samples. The document displayed is the fully formatted, ready-to-use analysis you’ll be able to download and apply the moment you buy. You’re viewing the final deliverable, identical to the file sent after payment, complete with conclusions and actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747216732537,"sku":"harrowinc-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harrowinc-five-forces-analysis.png?v=1772196084","url":"https:\/\/matrixbcg.com\/products\/harrowinc-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}